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Abstract
Background:  To determine monthly cost and cost effectiveness of bilateral prostaglandin/
prostamide therapy for lowering intraocular pressure (IOP) in patients taking bimatoprost 0.03%
(Lumigan®, Allergan, Inc.), latanoprost 0.005% (Xalatan®, Pfizer, Inc.), or travoprost 0.004%
(Travatan®, Alcon Laboratories, Inc.).
Methods: Drops in five new 2.5-mL bottles were counted and then averaged for each drug.
Average retail price was determined by surveys of pharmacies. Drop count, average retail price,
average wholesale price, and IOP reduction data were used to compute annual cost, and cost
effectiveness (annual cost-per-mm Hg of IOP reduction) of the three drugs.
Results: Drops per 2.5-mL bottle averaged 113 for bimatoprost 0.03%, 84 for latanoprost 0.005%,
and 83 for travoprost 0.004%. Average retail cost (2005) per bottle was $69.99 for bimatoprost
0.03%, $61.69 for latanoprost 0.005%, and $66.37 for travoprost 0.004%. The monthly retail cost
of bilateral therapy was $37.92 for bimatoprost 0.03%, $44.75 for latanoprost 0.005%, and $49.25
for travoprost 0.004%. Cost effectiveness ranges were $57 to $65 per mm Hg reduction in IOP
per year for bimatoprost, 0.03%, $67 to $90 per mm Hg for latanoprost 0.005%, and $74 to $84
per mm Hg for travoprost 0.004%.
Conclusion: Bimatoprost 0.03% had the lowest monthly and annual costs and the greatest cost
effectiveness for lowering IOP compared with latanoprost 0.005% and travoprost 0.004%.
Background
The prostamide bimatoprost and the prostaglandin ana-
logues latanoprost and travoprost are ocular hypotensive
lipids that are indicated for lowering intraocular pressure
(IOP) in patients with glaucoma or ocular hypertension.
The efficacy of bimatoprost 0.03% (Lumigan®, Allergan,
Inc. Irvine, CA), latanoprost 0.005% (Xalatan®, Pfizer,
Inc., New York, NY), and travoprost 0.004% (Travatan®,
Alcon Laboratories, Inc. Ft. Worth, TX) was superior to
timolol for lowering IOP in these patient populations [1-
3]. One [4] of two recent studies [4,5] demonstrated that
bimatoprost is statistically significantly more effective
than latanoprost in lowering IOP.
The costs (direct and indirect) of pharmaceuticals to
patients have become an important national issue. Man-
aged care organizations utilize pharmacoeconomic data
such as cost minimization and cost effectiveness when
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deciding which drugs to include in their formulary. Cost
minimization  involves choosing a drug based on direct
costs, whereas cost effectiveness is determined by dividing
the direct cost of the drug by its efficacy, defined in this
analysis as mm Hg of IOP reduction. The relationship
between decisions based on cost minimization and those
based on cost effectiveness analyses is shown in Table 1.
If the dispensable shelf life of an ophthalmic preparation
requires its disposal before the entire bottle of drug solu-
tion has been used [6], cost effectiveness can be affected.
Bimatoprost has a shelf life of 2 years [7], whereas latano-
prost must be used within 6 weeks of opening [8]. No
shelf life limitation is indicated in the current prescribing
information for travoprost [9]. Limited dispensable shelf
life is one reason for incomplete use of issued medication,
which may affect the number of bottles required for treat-
ment over time.
The objective of this study was to compare monthly costs
(based on retail and wholesale prices) and the cost effec-
tiveness of bilateral treatment with bimatoprost 0.03%,
latanoprost 0.005%, and travoprost 0.004% for reduction
of IOP in patients with glaucoma or ocular hypertension.
Methods
This prospective pharmacoeconomic study evaluated the
direct cost and cost effectiveness of prostaglandin/prosta-
mide therapy for reduction of IOP in patients with glau-
coma or ocular hypertension. The drugs studied were
bimatoprost 0.03% (Lumigan®, Allergan, Inc. Irvine, CA),
latanoprost 0.005% (Xalatan®, Pfizer, Inc., New York,
NY), and travoprost 0.004% (Travatan®, Alcon Laborato-
ries, Inc. Ft. Worth, TX).
Retail prices of the 3 drugs were obtained from 7 pharma-
cies representing both independent (Park Pharmacy) and
chain (Walgreens, Wal-Mart, Winn Dixie, K-Mart, Target,
and DrugStore.Com) businesses. The pharmacies were
located in Stuart, FL, except for Drugstore.com which is an
online pharmacy based in Bellevue, WA. All pharmacies
were chosen prior to their pricing being known and no
pharmacies were dropped from the study. Prices were
obtained during 3 different time periods: 1) during the
fall of 2001, when a drop-count study was also conducted,
2) during February 2003, and 3) during May 2005. Prices
were checked twice in 2 weeks and immediately recorded.
The contents of 5 new bottles (marked as containing 2.5
mL) of each drug (bimatoprost 0.03%, latanoprost
0.005%, and travoprost 0.004%) were measured in terms
of drops per bottle by a procedure designed to mimic
actual medication use by patients. Drops were counted
while the contents were at room temperature. Each bottle
was inverted to a vertical position and squeezed until 1
drop came out. The bottle was then placed upright. This
procedure was repeated until the bottle was emptied. The
same person dispensed all drops for all 3 drugs and was
masked to the purpose of the study and the identity of the
drugs. Because a secondary observer might be more likely
to miss seeing a drop, the same person that squeezed the
bottles also counted the drops. The average of the values
for the 5 bottles was used in further analyses.
Cost-minimization analysis was conducted using the
average retail price, determined from the pharmacy sur-
vey, for 1 bottle of drug from May 2005 and also with the
average wholesale price (AWP) from the same year. The
number of days per bottle was calculated by dividing the
number of drops per bottle by 2 (drops per day), based on
treatment of both eyes once per day. Annual usage (bot-
tles per year) was calculated by dividing 365 (days per
year) by the number of days per bottle. Annual cost is the
bottle cost times the annual usage, and the monthly cost
is the annual cost divided by 12 (months per year). An
additional analysis was made with the assumption that
patients occasionally misdirect their medication at instil-
lation and require 2 extra drops per week. For this calcula-
tion, annual usage was based on daily, bilateral dosing
plus 2 extra drops per week.
Table 1: Cost effectiveness example calculation
IOP reduction Direct costs Cost effectiveness calculations
Decision based on cost minimization:
Equal (10 mm Hg) Different ($500/yr vs. $400/yr) Drug A: $500/yr; 10 mm Hg 
reduction = $50 per mm Hg 
reduction
Drug B: $400/yr; 10 mm Hg 
reduction = $40 per mm Hg 
reduction
Decision based on cost effectiveness:
Different (10 mm Hg vs. 5 mm Hg) Different ($500/yr vs. $400/yr) Drug C: $500/yr; 10 mm Hg 
reduction = $50 per mm Hg 
reduction
Drug D: $400/yr; 5 mm Hg 
reduction = $80 per mm Hg 
reduction
IOP = intraocular pressure When the formulary inclusion decision process is based on cost minimization, Drug B is chosen over Drug A based on 
the difference in direct costs. When the decision is based on cost effectiveness, Drug C is chosen over Drug D in spite of the higher direct cost of 
Drug C, because Drug C is more cost effective.BMC Ophthalmology 2007, 7:16 http://www.biomedcentral.com/1471-2415/7/16
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Annual usage, annual cost, and monthly cost were also
considered with regard to drug dispensable shelf life. The
effect on treatment costs was found by comparing the
shelf life, based on prescribing information, with the
number of treatment days per bottle.
Cost effectiveness was determined by dividing the drug
cost (2005 AWP) by the drug's efficacy. In this study, effi-
cacy is defined as the degree of IOP reduction (mm Hg),
taken from the package insert for each drug [7-9]. Cost
effectiveness data for the three drugs in this study are
expressed as ranges calculated from the ranges of IOP low-
ering reported in the respective package inserts.
Results
The results from a survey of 7 different pharmacies regard-
ing the costs of 2.5 and 5-mL bottles of bimatoprost
0.03%, a 2.5-mL bottle of latanoprost 0.005%, and a 2.5-
mL bottle of travoprost 0.004% in the fall of 2001 appear
in Table 2. Drops from the 5-mL bottles were not counted,
nor were the costs for these bottles used in any of the cal-
culations; however, these data are presented to provide
additional information. The highest average cost was
found for bimatoprost 0.03%, followed by travoprost
0.004% and latanoprost 0.005%.
Due to inflation, new retail prices were obtained from the
same pharmacies in February 2003 (Table 3) and May
2005 (Table 4). The average retail price increased 19% for
bimatoprost 0.03%, 18% for travoprost 0.004%, and 8%
for latanoprost 0.005% from 2001 to 2003 (Table 5).
Over the next 2 years prices continued to increase. By May
2005, average retail prices for 2.5-mL bottles were $61.69
for latanoprost 0.005% (range $50.68 to $69.95), $66.37
for travoprost 0.004% (range $56.88 to $71.99), and
$69.99 for bimatoprost 0.03% (range $57.74 to $74.99).
This represented a further increase of 13% for bimatoprost
0.03%, 12% for travoprost 0.004%, and 21% for latano-
prost 0.005% from 2003 to 2005.
The number of drops counted from 2.5 mL bottles of the
3 drugs appears in Table 6. Bottles of bimatoprost 0.03%
had the greatest number of drops, followed by latanoprost
0.005%, and then by travoprost 0.004%. The standard
deviation of the number of drops per bottle was highest
for bimatoprost and lowest for latanoprost.
Based on average retail prices from 2005, calculations for
the number of days per bottle, annual usage, annual cost,
monthly cost, bilateral daily cost and cost per drop appear
in Table 7 for each of the 3 medications. With bilateral
therapy, the retail costs per day for these medications are
$1.24 for bimatoprost 0.03%, $1.46 for latanoprost
0.005%, and $1.60 for travoprost 0.004%. The costs were
lowest for bimatoprost 0.03% and highest for travoprost
0.004%, by a difference of 30%.
Similarly, Table 8 lists the annual and monthly costs of
the 3 medications but substitutes AWP from 2005 for
average retail price in the calculations. The AWP for one
bottle is lowest for latanoprost 0.005% and highest for
travoprost 0.004%, with a difference of only 1.5%. How-
ever, the annual and monthly costs based on AWP are
lowest for bimatoprost 0.03% and highest for travoprost
0.004%, with a difference of 37%.
The results of an analysis that assumes 2 doses missed the
eye per week (thus requiring reapplication) appear in
Table 9. A total of 834 drops per year are required for any
of the 3 drugs. Using this assumption and the average
retail price from 2005, the annual and monthly costs are
shown.
The shelf lives of bimatoprost 0.03% (2 years) and latan-
oprost 0.005% (42 days) were not limiting, and were
greater than or equal to the number of days per bottle
based on bilateral, daily dosing (bimatoprost 0.03% = 56
days, latanoprost 0.005% = 42 days). No limitation of the
shelf life for travoprost 0.004% appears in its prescribing
information [9]. Thus, when considering drug dispensa-
ble shelf life, no corrections were required for calculations
of annual usage, annual cost, and monthly cost for any of
the 3 medications.
Table 2: US retail drug prices, fall 2001
Bimatoprost 0.03%, 
2.5 mL
Bimatoprost 0.03%,
 5.0 mL ($ per 2.5 mL)
Latanoprost 0.005%, 
2.5 mL
Travoprost 0.004%, 
2.5 mL
Walgreens $54.99 $52.50 $53.99 --
Park Pharmacy $51.95 $50.98 $49.95 $49.95
WalMart $51.46 $51.89 $40.98 $48.62
Winn Dixie $44.50 $44.50 $46.00 $47.00
K-Mart $56.97 $51.99 $49.99 $53.97
Target $56.39 $51.35 $41.99 $53.69
DrugStore.Com $50.10 $50.10 $46.90 $47.40
Average $52.34 $50.47 $47.11 $50.11BMC Ophthalmology 2007, 7:16 http://www.biomedcentral.com/1471-2415/7/16
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Table 3: US retail drug prices, February 2003
Bimatoprost 0.03%, 
2.5 mL
Bimatoprost 0.03%, 
5.0 mL ($ per 2.5 mL)
Latanoprost 0.005%,
 2.5 mL
Travoprost 0.004%, 
2.5 mL
Walgreens $61.99 $59.00 $56.99 --
Park Pharmacy $56.90 $55.45 $52.90 $56.90
WalMart $54.72 $52.73 $41.99 $54.72
Winn Dixie $84.95 $50.98 $52.95 $71.95
K-Mart $61.97 $56.99 $52.99 $61.97
Target $61.64 $48.00 $46.69 $57.84
DrugStore.Com $52.64 $50.10 $51.55 $50.86
Average $62.12 $53.86 $50.87 $59.04
Table 4: US retail drug prices, May 2005
Bimatoprost 0.03%,
 2.5 mL
Bimatoprost 0.03%, 
5.0 mL ($ per 2.5 mL)
Latanoprost 0.005%,
 2.5 mL
Travoprost 0.004%, 
2.5 mL
Walgreens $74.99 $71.50 $65.99 $71.99
Park Pharmacy $68.95 $67.98 $63.98 $64.95
WalMart $69.32 $63.23 $50.68 $64.88
Winn Dixie $71.95 $63.48 $69.95 $66.95
K-Mart $74.97 $69.49 $62.99 $70.97
Target $71.99 $65.75 $59.99 $67.99
DrugStore.Com $57.75 $55.12 $58.22 $56.88
Average $69.99 $65.22 $61.69 $66.37
Table 5: Percentage increase in average retail price
Fall 2001 to February 2003 February 2003 to May 2005 Fall 2001 to May 2005
Bimatoprost 0.03% 19% 13% 34%
Latanoprost 0.005% 8% 21% 31%
Travoprost 0.004% 18% 12% 32%
Table 6: Drops per bottle
Bimatoprost 0.03% Latanoprost 0.005% Travoprost 0.004%
Bottle 1 118 83 88
Bottle 2 130 88 97
Bottle 3 100 82 78
Bottle 4 103 85 75
Bottle 5 115 81 79
Average ± SD 113 +/- 12 84 +/- 3 83 +/- 9BMC Ophthalmology 2007, 7:16 http://www.biomedcentral.com/1471-2415/7/16
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Table 8: Cost-minimization analysis of bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; average wholesale price
Drug Drops per 
Bottle
Days per Bottle Annual Usage 
(bottles per year)
Bottle Cost* 
($ per bottle)
Annual Cost Monthly Cost
Bimatoprost 0.03% 113 56 6.5 $62.10 $404 $33.67
Latanoprost 0.005% 84 42 8.7 $61.29 $533 $44.42
Travoprost 0.004% 83 41 8.9 $62.19 $553 $46.08
* Average Wholesale Price, 2005
Table 7: Cost-minimization analysis of bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; average retail price
Drops per 
Bottle
Days per 
Bottle
Annual 
Usage 
(bottles per 
year)
Bottle 
Cost* ($ per 
bottle)
Annual 
Cost
Monthly 
Cost
Cost per 
Day 
(bilateral 
therapy)
Cost per 
Drop
Bimatopros
t 0.03%
113 56 6.5 $69.99 $455 $37.92 $1.24 $0.62
Latanoprost 
0.005%
84 42 8.7 $61.69 $537 $44.75 $1.46 $0.73
Travoprost 
0.004%
83 41 8.9 $66.37 $591 $49.25 $1.60 $0.80
* Average retail price, 2005
Table 9: Cost-minimization analysis of bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; assuming 2 drops missed the 
eye per week
Drug Drops per 
Bottle
Drops 
Administered 
per Year 
(bilaterally)
Drops 
Missed 
Hitting the 
Eye per 
Year
Total Drops 
per Year
Bottles 
per Year
Bottle Cost* 
($ per bottle)
Annual 
Cost
Monthly 
Cost
Bimatoprost 
0.03%
113 730 104 834 7.4 $69.99 $518 $43.17
Latanoprost 
0.005%
84 730 104 834 9.9 $61.69 $611 $50.92
Travoprost 
0.004%
83 730 104 834 10.0 $66.37 $664 $55.33
*Average retail price, 2005
Table 10: Cost effectiveness analysis of bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Bimatoprost 0.03% Latanoprost 0.005% Travoprost 0.004%
Annual Cost* $455 $537 $591
IOP Reduction, Lower 
Value†(mm Hg)
767
IOP Reduction, Upper 
Value†(mm Hg)
888
Cost Effectiveness Range 
($/mm Hg decrease in IOP)
$57–$65/mm Hg $67–$90/mm Hg $74–$84/mm Hg
IOP = intraocular pressure
*Average retail price, 2005, before adjustment for drug shelf life.
†Ranges of IOP reduction efficacy reported in package inserts [7–9].BMC Ophthalmology 2007, 7:16 http://www.biomedcentral.com/1471-2415/7/16
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Results of the cost effectiveness analysis appear in Table
10. The annual costs used for these calculations were
based on average retail price in 2005 from Table 4. The
efficacy ranges were taken from the most recent prescrib-
ing information [7-9]. For bimatoprost 0.03%, an annual
cost of $455 with an efficacy range of 7 to 8 mm Hg of IOP
reduction [7] yielded a range of cost effectiveness from
$57 to $65 per 1 mm Hg decrease in IOP. Bimatoprost
0.03% was more cost effective than latanoprost 0.005%
and travoprost 0.004%.
Discussion
Bimatoprost 0.03% was the most economical of the 3
prostaglandin/prostamide IOP-lowering drugs evaluated
in this study in terms of both cost minimization and cost
effectiveness.
The monthly and annual costs of bimatoprost 0.03% were
the lowest of the 3 medications in the cost minimization
analyses because of the greater number of drops dis-
pensed per bottle, a measurement that mimics actual use
of medication by patients. In this study, means of 113, 84,
and 83 drops per 2.5 mL bottle of bimatoprost, latano-
prost, and travoprost, respectively, were measured. The
relative rank of bimatoprost over latanoprost and travo-
prost is consistent with 3 previous studies which meas-
ured 111, 98, and 103 drops [10]; 103, 92, and 98 drops
[11]; and 111.0, 94.3, 81.4 drops (vertical position) [12]
per 2.5 mL bottle of bimatoprost, latanoprost, and travo-
prost, respectively. The total volumes of medications dis-
pensed in those studies were 3.3, 3.05, and 3.0 mL [10];
3.06, 2.98, and 2.92 mL [11]; and 3.17, 3.02, 2.54 mL [12]
per 2.5 mL bottle of bimatoprost, latanoprost, and travo-
prost, respectively.
Bimatoprost remained the most economical whether or
not product dispensable shelf life was accounted for,
whether average retail prices or average wholesale prices
were used in the calculations, or if additional medication
was needed due to occasional misdirection of drops dur-
ing instillation. Overall, the monthly and annual costs of
binocular therapy with latanoprost 0.005% and travo-
prost 0.004% ranged from 18% to 37% more than for
bimatoprost 0.03%, depending on the premise of the
analysis. The results of another cost comparison of these
three drugs by Mick et al. [11] also found bimatoprost to
be the least expensive, but the cost differences between the
3 drugs were less. These investigators demonstrated that
the annual cost of monocular therapy with bimatoprost
was less than with latanoprost, travoprost, or unopros-
tone. In addition, they found that bimatoprost had the
largest percentage of overfill from the labeled volume of
2.5-mL compared with the other three medications.
Overall, prices for these medications increased 31 to 34%
from 2001 to 2005, while the consumer price index
increased 10% [13]. It is interesting that the disparity
between the pharmaceutical price increase and the Con-
sumer Price Index was similar for all three drugs. The rea-
sons for this are beyond the scope of this paper; but
clearly, the cost of pharmaceuticals is an important issue
today and will likely remain so into the future.
Bimatoprost 0.03% was the most cost effective (i.e., had
the lowest cost per mm Hg of IOP reduction) of the three
drugs evaluated, a finding consistent with other pharmac-
oeconomic studies of IOP-lowering medications [14].
Efficacy in this study was based on ranges of IOP reduc-
tions published in the prescribing information for each
drug, but greater differences in efficacy may be observed
among individual patients or in clinical studies. In con-
trast to the similar IOP reduction ranges documented in
the prescribing information for these drugs, Noecker et al.
[4] demonstrated that bimatoprost 0.03% had IOP reduc-
tion efficacy that was superior to latanoprost 0.005%
[7,8]. Wider differences in efficacy may contribute to more
disparate cost effectiveness, as shown in analyses based on
the number of patients that achieved a target decrease in
IOP [15] or that used a patient-weighted average IOP
reduction based on IOP lowering reports for the 3 drugs
from over 20 different studies [16]. These studies showed
that bimatoprost produced a larger percent change in IOP,
and was thus more cost effective than latanoprost [15,16]
and travoprost [16]. These analyses did not account for
differences in the dispensation of the medications, but do
suggest that the differences in the cost effectiveness of
these 3 drugs may be greater in practice than reported
here.
This study was limited by the number of bottles of each
drug that were counted. The volume of ophthalmic solu-
tion (drops per bottle) could vary considerably with each
medication and across medications. Each medication in
this study was dispensed from a vertically-positioned bot-
tle, but the angle of instillation has been found to differ-
entially affect drop size and thus the number of days of
therapy achieved [12]. Additionally, a small number of
pharmacies were surveyed, although most were members
of large chains that were felt to be representative retailers
to consumers. One local non-chain pharmacy (Park) was
chosen to represent that particular segment of the market.
We tried to be unbiased in our pharmacy selection; how-
ever, it is clear that retail costs to patients with no drug
coverage may vary among these and other pharmacies.
Furthermore, although patients with drug coverage may
be less affected depending on their deductible level, these
cost variances may still be consequential.BMC Ophthalmology 2007, 7:16 http://www.biomedcentral.com/1471-2415/7/16
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This study did not address different drug tolerabilities [5]
which may or may not cause patients to discontinue ther-
apy, nor did it address the concept of persistency. Parrish
et al. [5] found that latanoprost exhibited greater ocular
tolerability than bimatoprost or travoprost. Patients using
a less tolerable drug might also use artificial tears to
increase ocular comfort, which could increase the total
cost of therapy. This determination was beyond the scope
of this study. Drug discontinuation rates can also affect
cost. Greater patient persistency with one medication over
another would potentially lower the overall cost of ther-
apy with that drug, taking into account the associated cost
of additional physician visits if a patient needs to switch
to another drug. Although Reardon et al. [17] showed rel-
atively better persistency with latanoprost, a more recent
study showed comparable persistency among latanoprost,
bimatoprost, and travoprost, and slightly better adher-
ence with bimatoprost than latanoprost [18]. Even with a
distinct between-drug difference in persistency, it is diffi-
cult to quantitate the effect of persistency on therapy cost,
particularly across different health care delivery settings.
Such costs would have to be amortized over variable dura-
tions of the patients' therapy. Though such costs may be
real, assigning additional costs related to tolerability or
persistence would have introduced an inexact variable
into this objective quantitative analysis.
Conclusion
The data provided by this analysis should be useful to
those interested in the costs of common glaucoma drugs.
Although cost is an important factor, clearly it should not
be the only consideration in choosing a specific medica-
tion. Factors to be considered include efficacy of IOP
reduction, cost to the patient, cost effectiveness, product
shelf life, persistency, and tolerability. Ultimately, choos-
ing the best drug for an individual patient is a decision to
be made between physician and patient.
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